Chronic Total Occlusions (CTO): 60 Second Insights
Published: 08 March 2018
-
Views:
2186
-
Likes:
7
-
Views:
2186
-
Likes:
7
-
Up Next -
1m 18sPart 9 | Session 6 Carlos Di Mario
-
1m 7sPart 9 | Session 7 Gerald Werner
-
37sPart 1 Ajay Kirtane Ajay J Kirtane
-
52sPart 2 | Session 1 Ajay Kirtane Ajay J Kirtane
-
1mPart 2 | Session 2 Simon Walsh Simon J Walsh
-
49sPart 2 | Session 3 Paul Knaapen Paul Knaapen
-
27sPart 2 | Session 4 Emmanouil Brilakis Emmanouil S Brilakis
-
1m 36sPart 2 | Session 5 Carlos Di Mario Carlo Di Mario
-
55sPart 2 | Session 6 Patrick Serruys Patrick W Serruys
-
55sPart 2 | Session 7 Gerald Werner Gerald S Werner
-
25sPart 3 | Session 1 Ajay Kirtane Ajay J Kirtane
-
46sPart 3 | Session 2 Simon Walsh Simon J Walsh
-
1mPart 3 | Session 3 Paul Knaapen Paul Knaapen
-
35sPart 3 | Session 4 Emmanouil Brilakis Emmanouil S Brilakis
-
1m 9sPart 3 | Session 5 Carlos Di Mario Carlo Di Mario
-
57sPart 3 | Session 6 Patrick Serruys Patrick W Serruys
-
1m 12sPart 3 | Session 7 Gerald Werner Gerald S Werner
-
46sPart 4 | Session 1 Ajay Kirtane
-
1m 6sPart 4 | Session 2 Simon Walsh Simon J Walsh
-
1m 7sPart 4 | Session 3 Paul Knaapen Paul Knaapen
-
46sPart 4 | Session 4 Emmanouil Brilakis Emmanouil S Brilakis
-
1m 11sPart 4 | Session 5 Patrick Serruys Patrick W Serruys
-
1m 24sPart 4 | Session 6 Gerald Werner Gerald S Werner
-
38sPart 5 | Session 1 Ajay Kirtane Ajay J Kirtane
-
46sPart 5 | Session 2 Simon Walsh Simon J Walsh
-
55sPart 5 | Session 3 Paul Knaapen Paul Knaapen
-
41sPart 5 | Session 4 Emmanouil Birlakis Emmanouil S Brilakis
-
56sPart 5 | Session 5 Carlos Di Mario Carlo Di Mario
-
50sPart 5 | Session 6 Patrick Serruys Patrick W Serruys
-
47sPart 5 | Session 7 Gerald Werner Gerald S Werner
-
42sPart 6 | Session 1 Ajay Kirtane Ajay J Kirtane
-
1m 1sPart 6 | Session 2 Simon Walsh Simon J Walsh
-
1m 2sPart 6 | Session 3 Paul Knaapen Paul Knaapen
-
35sPart 6 | Session 4 Emmanouil Birkalis Emmanouil S Brilakis
-
40sPart 6 | Session 5 Carlos Di Mario Carlo Di Mario
-
1m 18sPart 6 | Session 6 Patrick Serruys Patrick W Serruys
-
1m 7sPart 6 | Session 7 Gerald Werner Gerald S Werner
-
57sPart 7 | Session 1 Ajay Kirtane Ajay J Kirtane
-
1m 15sPart 7 | Session 2 Simon Walsh Simon J Walsh
-
1m 5sPart 7 | Session 3 Paul Knaapen Paul Knaapen
-
49sPart 7 | Session 4 Emmanouil Birkalis Emmanouil S Brilakis
-
1m 25sPart 7 | Session 5 Carlos Di Mario Carlo Di Mario
-
1m 36sPart 7 | Session 6 Patrick Serruys Patrick W Serruys
-
1m 24sPart 7 | Session 7 Gerald Werner Gerald S Werner
-
45sPart 8 | Session 1 Ajay Kirtane Ajay J Kirtane
-
37sPart 8 | Session 2 Simon Walsh Simon J Walsh
-
1mPart 8 | Session 3 Paul Knaapen Paul Knaapen
-
37sPart 8 | Session 4 Emmanouil Birlakis Emmanouil S Brilakis
-
1m 4sPart 8 | Session 5 Carlos Di Mario Carlo Di Mario
-
1m 5sPart 8 | Session 6 Patrick Serruys Patrick W Serruys
-
1m 7sPart 8 | Session 7 Gerald Werner Gerald S Werner
-
48sPart 9 | Session 1 Ajay Kirtane Ajay J Kirtane
-
52sPart 9 | Session 2 Simon Walsh Simon J Walsh
-
1m 4sPart 9 | Session 3 Paul Knaappen Paul Knaapen
-
53sPart 9 | Session 4 Emmanouil Brilakis Emmanouil S Brilakis
Overview
A series of 60-second interviews where Ajay Kirtane, Simon Walsh, Paul Knappen, Emmanouil Brilakis, Carlos Di Mario, Partick Serruys and Gerald Werner provide their thoughts on CTOs.
More from this programme
Part 1
Are CTOs important to the management of angina in your patients?
| 1 session | |
| Ajay Kirtane | Watch now |
Part 2
What trials are needed to advance the CTO field?
Part 3
What is your preferred imaging modality for CTOs?
Part 4
What is your preferred CTO wire strategy, and why?
Part 5
What is the biggest advance in CTO treatment in the past 5 years?
Part 6
What devices should be developed to further advance CTO management?
Part 7
The data for CTO is mixed, with clinical trials showing no clear benefit, should we keep on doing CTO's?
Part 8
Retrograde or anterograde? What is your preferred strategy?
Part 9
How would you recommend someone starts a CTO program?
Faculty Biographies
Patrick W Serruys
Prof Patrick W Serruys has been a senior interventional cardiologist since 1977, Chief of Interventional Research since 1988, the Chief of Interventional Cardiology at the Thorax Center from 1997-2012, and Prof. of Medicine till April 1st 2014 at Erasmus MC. In 2006, Prof Serruys and Prof John Ormiston developed fully biodegradable drug-eluting scaffolds.
Prof Serruys has won career achievement awards from the TCT, the American College of Cardiology, and the European Society of Cardiology.
Currently, he is Professor of Cardiology in the Cardiovascular Science Division of the National Heart and Lung Institute (NHLI) of Imperial College in London (UK).